Development
Sarepta Therapeutics, Inc.
SRPT
$16.26
-$0.49-2.93%
NASDAQ
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Net Income | 23.81% | 3.54% | -79.16% | -212.78% | -67.99% |
| Total Depreciation and Amortization | 6.05% | 5.40% | 5.39% | 6.94% | 10.44% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 25.53% | 38.37% | 178.52% | 1,956.04% | 950.84% |
| Change in Net Operating Assets | -1,118.87% | -761.03% | -214.69% | -48.12% | 59.79% |
| Cash from Operations | -53.99% | -105.40% | -52.03% | -19.12% | 26.59% |
| Capital Expenditure | -146.91% | -159.44% | -67.16% | -51.83% | 19.92% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 91.17% | 97.43% | 117.60% | 49.59% | -290.31% |
| Cash from Investing | 84.16% | 91.35% | 113.05% | 44.40% | -311.32% |
| Total Debt Issued | -- | -100.00% | -- | -- | -- |
| Total Debt Repaid | -- | 100.00% | -- | -- | -- |
| Issuance of Common Stock | 70.58% | -89.36% | -89.57% | -90.61% | -94.72% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 172.52% | 172.37% | -- | -- | -- |
| Cash from Financing | -46.24% | -82.64% | -40.26% | -41.58% | -58.60% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 52.46% | 9.80% | 98.03% | -42.64% | -285.68% |